Switch theme
Sign up to access all valuation multiples
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
2018
120
Last FY Revenue $54.2M
Last FY EBITDA -$43.7M
$119M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Celularity achieved revenue of $54.2M and an EBITDA of -$43.7M.
Celularity expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celularity valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $54.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $39.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 72% | XXX | XXX | XXX |
| EBITDA | XXX | -$43.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -81% | XXX | XXX | XXX |
| EBIT | XXX | -$38.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -71% | XXX | XXX | XXX |
| Net Profit | XXX | -$57.9M | XXX | XXX | XXX |
| Net Margin | XXX | -107% | XXX | XXX | XXX |
| Net Debt | XXX | $41.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Celularity's stock price is $2.
Celularity has current market cap of $50.8M, and EV of $119M.
See Celularity trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $119M | $50.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Celularity has market cap of $50.8M and EV of $119M.
Celularity's trades at 2.2x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Celularity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celularity's P/E ratio is not available.
See valuation multiples for Celularity and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50.8M | XXX | $50.8M | XXX | XXX | XXX |
| EV (current) | $119M | XXX | $119M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -18.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCelularity's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.6M for the same period.
Celularity's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celularity's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Celularity and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -81% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 143% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celularity acquired XXX companies to date.
Last acquisition by Celularity was XXXXXXXX, XXXXX XXXXX XXXXXX . Celularity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Celularity founded? | Celularity was founded in 2018. |
| Where is Celularity headquartered? | Celularity is headquartered in United States of America. |
| How many employees does Celularity have? | As of today, Celularity has 120 employees. |
| Who is the CEO of Celularity? | Celularity's CEO is Dr. Robert J. Hariri, M.D.,PhD. |
| Is Celularity publicy listed? | Yes, Celularity is a public company listed on NAS. |
| What is the stock symbol of Celularity? | Celularity trades under CELU ticker. |
| When did Celularity go public? | Celularity went public in 2021. |
| Who are competitors of Celularity? | Similar companies to Celularity include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celularity? | Celularity's current market cap is $50.8M |
| Is Celularity profitable? | Yes, Celularity is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
